Cargando…

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment

BACKGROUND: Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. OBJECTIVE AND...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönfelder, Kristina, Schuh, Helene, Pfister, Frederick, Krämer, Julia, Eisenberger, Ute, Skuljec, Jelena, Hackert, Jana, Ruck, Tobias, Pfeuffer, Steffen, Fleischer, Michael, Gäckler, Anja, Hagenacker, Tim, Kribben, Andreas, Meuth, Sven G, Kleinschnitz, Christoph, Pul, Refik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521349/ https://www.ncbi.nlm.nih.gov/pubmed/34165361 http://dx.doi.org/10.1177/13524585211022719

Ejemplares similares

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Immunotherapies in chronic adhesive arachnoiditis - A case series and literature review
por: Hackert, Jana, et al.
Publicado: (2021)

Analysis of Free Circulating Messenger Ribonucleic Acids in Serum Samples from Late-Onset Spinal Muscular Atrophy Patients Using nCounter NanoString Technology
por: Leo, Markus, et al.
Publicado: (2023)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

Absence of Regulatory T Cells Causes Phenotypic and Functional Switch in Murine Peritoneal Macrophages
por: Skuljec, Jelena, et al.
Publicado: (2018)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients
por: Pul, Refik, et al.
Publicado: (2012)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis
por: Schroeter, Christina B., et al.
Publicado: (2022)

Randomized, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants
por: Gäckler, Anja, et al.
Publicado: (2019)

Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome
por: Mülling, Nils, et al.
Publicado: (2020)

Severe and long-lasting alteration of albumin redox state by plasmapheresis
por: Boss, Kristina, et al.
Publicado: (2022)

Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2021)

CIDP, myasthenia gravis, and membranous glomerulonephritis – three autoimmune disorders in one patient: a case report
por: Bolz, Saskia, et al.
Publicado: (2018)

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study
por: Ruck, Tobias, et al.
Publicado: (2019)

Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation
por: Lindemann, Monika, et al.
Publicado: (2021)

Brainstem Infarction in Immunodeficiency Identified as Adenosine Deaminase 2 Deficiency: Case Report
por: Oster, Christoph, et al.
Publicado: (2023)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Induction of Survival of Motor Neuron (SMN) Protein Deficiency in Spinal Astrocytes by Small Interfering RNA as an In Vitro Model of Spinal Muscular Atrophy
por: Leo, Markus, et al.
Publicado: (2022)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients—Lessons Learned From SARS and MERS
por: Möhn, Nora, et al.
Publicado: (2020)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Disease-modifying therapies for relapsing/active secondary progressive multiple sclerosis – a review of population-specific evidence from randomized clinical trials
por: Bayas, Antonios, et al.
Publicado: (2023)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

Experience in Multiple Sclerosis Patients with COVID-19 and Disease-Modifying Therapies: A Review of 873 Published Cases
por: Möhn, Nora, et al.
Publicado: (2020)

MOG antibody–associated encephalomyelitis mimicking bacterial meningomyelitis following ChAdOx1 nCoV-19 vaccination: a case report
por: Escolà, Jordi Kühne, et al.
Publicado: (2022)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i094q9jcuidefol0ebql2i4d62